Jazz Pharmaceuticals plc
JAZZ
Market Cap$7.75B
Close$
$249.48
94.9% upside
Current Fair Value
94.9% upsideUndervalued by 94.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $7.75 Billion |
|---|---|
| Enterprise Value | $12.07 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $9.06 |
| Beta | 0.34 |
| Outstanding Shares | 61,194,000 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -19.31 |
|---|---|
| PEG | 3.67 |
| Price to Sales | 1.94 |
| Price to Book Ratio | 2.13 |
| Enterprise Value to Revenue | 2.95 |
| Enterprise Value to EBIT | -43.95 |
| Enterprise Value to Net Income | -30 |
| Total Debt to Enterprise | 0.46 |
| Debt to Equity | 1.49 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Jazz Pharmaceuticals plc
1,210 employeesJazz Pharmaceuticals plc is a biopharmaceutical company based in Ireland. It was founded in 2003. One of the company's most significant products is the United States Food and Drug Administration approved drug Xyrem , the sodium salt of...